Test Price
1,200 AED✅ Home Collection Available
Chimerism Pre-Engraftment Analysis in UAE | 1200 AED | DHA-Compliant Molecular Monitoring
Executive Summary & Core Metrics
UAE’s Most Trusted Chimerism Pre‑Engraftment Analysis — DHA‑Licensed Molecular Genetics Service
- 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited PCR‑STR fragment analysis with capillary electrophoresis.
- VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection — Available daily from 8 AM to 11 PM.
- Post‑Test Genetic Counselling — Complimentary telephone consultation with our Consultant Medical Geneticist.
- Insurance Support — Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
Chimerism pre‑engraftment analysis is a highly sensitive DNA‑based molecular assay that quantifies the percentage of donor versus recipient cells following hematopoietic stem cell transplantation. This test enables clinicians to monitor engraftment status, detect early graft failure, and identify impending relapse using PCR‑based Short Tandem Repeat (STR) fragment analysis coupled with capillary electrophoresis. Utilising a peripheral whole blood specimen collected in EDTA, the assay achieves a sensitivity threshold below 1% mixed chimerism, providing definitive cellular lineage discrimination critical for tailoring immunosuppressive therapy and guiding post‑transplant clinical decisions.
Comparative Performance Overview
| Feature | Our Chimerism Pre‑Engraftment Test | Standard Alternative Lab |
|---|---|---|
| Methodology | PCR‑STR Fragment Analysis with Capillary Electrophoresis (ISO 18385‑certified workflow) | Flow cytometry or FISH; reduced donor‑recipient discrimination |
| Sensitivity | 99.9% (detects <1% mixed chimerism) | Typically 90–95%; higher limit of detection |
| Turnaround Time | 7 working days (sample received by 11 AM) | 10–14 days; frequent batching delays |
| Accreditation | ISO 9001:2015 (Cert. INT/EGQ/2509DA/3139) | Variable; often lacks transplant‑specific QA |
| Sample Collection | VIP Mobile Phlebotomy with cold‑chain transport, 8 AM – 11 PM daily | In‑clinic draw only; no temperature‑controlled logistics |
Physician Insight & Safety Protocols
“Chimerism monitoring represents a cornerstone of precision post‑transplant care. The STR‑based pre‑engraftment assay provides the quantitative clarity needed to distinguish stable engraftment from impending graft rejection or disease relapse. As a Consultant Medical Geneticist, I emphasise that every laboratory result must be interpreted alongside the patient’s full clinical picture, including haematological parameters and physical examination findings. This integrated approach ensures the safest therapeutic adjustments and the best possible long‑term outcomes for transplant recipients.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Protocol & Patient Safety
⚠️ Medication Continuation Warning
Do not discontinue or alter any prescribed immunosuppressive or anticoagulant therapy without direct instruction from your treating haematologist. Abrupt changes may compromise graft stability or increase bleeding risk during phlebotomy.
Clinical Exclusion Criteria & Emergency Red Flags
Exclusion Criteria: Patients currently on anticoagulant therapy must inform the phlebotomist prior to sample collection to enable specialised venipuncture handling and minimise haematoma risk. ER Red Flags: If you experience fever ≥38.5°C, uncontrolled bleeding, severe abdominal or chest pain, shortness of breath, or any signs of systemic infection following your transplant, seek emergency medical care immediately regardless of your test schedule.
Patient FAQ & Clinical Guidance
1. What is chimerism pre‑engraftment analysis and why is it performed?
Chimerism pre‑engraftment analysis is a DNA‑based molecular test that uses Short Tandem Repeat fingerprinting to precisely quantify the proportion of donor‑derived cells circulating in the recipient’s blood after a hematopoietic stem cell transplant. It is performed to confirm successful donor cell engraftment, detect early graft failure before clinical symptoms appear, and identify mixed chimerism that may herald disease relapse, enabling timely intervention.
2. When is the ideal time to perform this test?
The test is optimally scheduled 14 to 21 days after the stem cell infusion. This window aligns with the expected onset of donor cell engraftment and provides the earliest actionable data on transplant success. Serial monitoring at defined intervals thereafter may be ordered by your transplant physician to track chimerism trends over time.
3. What do my chimerism results indicate?
A donor chimerism level above 95% generally indicates successful full engraftment, suggesting the donor marrow is producing the majority of blood cells. Mixed chimerism (donor percentage between 5% and 95%) may signal graft rejection, dwindling donor cell populations, or early relapse, and will likely prompt further clinical evaluation or adjustment of immunosuppressive therapy. Levels below 5% are considered graft failure and require immediate haematology review.
UAE Regulatory & Data Privacy Adherence
🔒 Your Data, Your Rights — Fully Compliant with UAE Federal Law
All chimerism testing data and personal health information are processed and stored in strict accordance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. These frameworks mandate rigorous encryption, access controls, and patient consent protocols for the handling of genomic and transplant‑related medical records.
Additionally, all clinical testing procedures, sample collection safety standards, and patient consent documentation adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability, ensuring full accountability and traceability throughout the diagnostic pathway. Your genomic privacy is protected by design and by default.
Clinical & Logistical Metadata
| Test Name | Chimerism Pre‑Engraftment Analysis (STR‑PCR) |
| Price (AED) | 1,200 AED |
| Turnaround Time | 7 working days |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) |
| Methodology Used | PCR‑Short Tandem Repeat (STR) Fragment Analysis with Capillary Electrophoresis |
| ICD‑10‑CM Code | Z94.8 (Other transplanted organ and tissue status) |
| LOINC Code | 43763-6 (Chimerism analysis in Blood by STR) |
| DHA Facility License & Lab Address | DHA Facility License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians